TGTX TG Therapeutics, Inc.

NASDAQ
$57.43

TG Therapeutics, Inc. (TGTX) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is $0.36 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +12.5% since its last earnings release on August 3, 2026.

TG Therapeutics Missed Expectations, Raises Guidance
Monday, August 3, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 7:00 AM ET
Earnings Whisper
-
vs $0.36
Rev est $247.16M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $52.97

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About TG Therapeutics, Inc.

TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.